Ferulic Acid Carbamate Derivatives for Alzheimer's Disease
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ferulic Acid Carbamate Derivatives for Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>BuChE IC₅₀ (nM)</td>
</tr>
<tr>
<td class="label">5c</td>
<td>15.2</td>
</tr>
<tr>
<td class="label">5e</td>
<td>18.7</td>
</tr>
<tr>
<td class="label">5g</td>
<td>22.4</td>
</tr>
<tr>
<td class="label">5h</td>
<td>28.1</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Donepezil/Rivastigmine</td>
</tr>
<tr>
<td class="label">Primary target</td>
<td>AChE (+ weak BuChE)</td>
</tr>
<tr>
<td class="label">Antioxidant</td>
<td>No</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>AChE > BuChE</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Moderate</td>
</tr>
</table>
Ferulic acid carbamate derivatives represent a novel class of dual-targeting therapeutics for Alzheimer's disease (AD) that simultaneously inhibit butyrylcholinesterase (BuChE) and activate the Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway. This approach addresses two key pathological hallmarks of AD: cholinergic deficit and oxidative stress.
The lead compounds from this series, particularly 5c, 5g, and 5h, demonstrate exceptional BuChE selectivity (>150-fold over acetylcholinesterase/AChE), neuroprotective effects against oxidative damage and amyloid-beta toxicity, and in vivo efficacy in transgenic AD models["@liu2019"].
Ferulic Acid: The Parent Compound
Ferulic acid (4-hydroxy-3-methoxycinnamic acid) is a natural phenolic compound found in various plant sources including wheat, rice, oats, and fruits. It exhibits well-documented neuroprotective properties:
- Antioxidant activity: Scavenges reactive oxygen species (ROS) and enhances endogenous antioxidant defenses
- Anti-inflammatory effects: Modulates NF-κB signaling and reduces neuroinflammation
- Anti-amyloid properties: Inhibits Aβ aggregation and reduces plaque formation
- Neuroprotection: Protects neurons against various toxic insults including oxidative stress and excitotoxicity
However, ferulic acid's clinical translation has been limited by its
poor blood-brain barrier (BBB) permeability and rapid metabolism. The carbamate derivative approach addresses these pharmacokinetic limitations while enhancing target engagement.
Carbamate Derivative Design
The carbamate derivative strategy involves conjugating ferulic acid with carbamate moieties to improve:
Blood-brain barrier penetration: Carbamate functional groups enhance lipophilicity
Target engagement: Carbamates form reversible covalent bonds with cholinesterases
Metabolic stability: Carbamate linkage provides resistance to rapid degradationStructure-Activity Relationships (SAR)
Key findings from the SAR studies include[@lao2026]:
- Substitutions at the para-position of the phenyl ring influence both BuChE selectivity and Nrf2 activation
- Compound 5c showed >150-fold selectivity for BuChE over AChE
- The carbamate linkage is critical for both cholinesterase inhibition and maintaining antioxidant properties
- Optimal chain length and terminal group modification enhance CNS drugability
BuChE Inhibition Mechanism
Butyrylcholinesterase in Alzheimer's Disease
BuChE (also known as pseudocholinesterase or pseudo-acetylcholinesterase) is increasingly recognized as a therapeutically important target in AD[@kumar2020]:
- Cholinergic hypothesis extension: While AChE activity decreases in early AD, BuChE activity progressively increases with disease progression
- Amyloid interaction: BuChE co-localizes with amyloid plaques and may accelerate Aβ aggregation
- Glial cell association: BuChE is expressed in activated microglia and astrocytes surrounding plaques
Mechanism of Carbamate Inhibition
Carbamate derivatives inhibit BuChE through a reversible carbamylation mechanism:
The carbamate group forms a covalent bond with the serine hydroxyl group in BuChE's active site
This blocks acetylcholine hydrolysis, restoring cholinergic neurotransmission
The carbamyl-serine adduct dissociates slowly, providing prolonged inhibition
Unlike organophosphates, carbamates do not form irreversibly phosphorylated intermediatesThe >150-fold selectivity for BuChE over AChE observed in compounds 5c and 5e is particularly valuable because:
- AChE inhibition can cause peripheral cholinergic side effects
- Selective BuChE inhibition preserves normal cholinergic signaling while targeting pathological activity
- This profile may be especially beneficial in moderate-to-severe AD where BuChE activity is elevated
Nrf2 Activation Pathway
The Nrf2-ARE Pathway in Neurodegeneration
The Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway is the master regulator of cellular antioxidant response[@sandberg2021]:
- Nrf2 normally binds to Keap1 (Kelch-like ECH-associated protein 1) in the cytoplasm
- Oxidative stress causes Nrf2 dissociation and nuclear translocation
- Nrf2 binds to Antioxidant Response Elements (ARE) in DNA
- This transcription activates >200 antioxidant and cytoprotective genes including:
- HO-1 (heme oxygenase-1): degrades pro-oxidant heme, produces biliverdin
- GCLM (glutamate-cysteine ligase modifier subunit): rate-limiting step in glutathione synthesis
- NQO1 (NAD(P)H quinone dehydrogenase 1): detoxification enzyme
- SOD (superoxide dismutase): scavenges superoxide radicals
In AD, the Nrf2 pathway is
dysfunctional, leading to inadequate antioxidant responses against oxidative stress from Aβ toxicity, mitochondrial dysfunction, and neuroinflammation.
Activation by Carbamate Derivatives
The ferulic acid carbamate derivatives activate Nrf2 through Keap1-Nrf2 dissociation[@lao2026]:
The compounds directly interact with Keap1's cysteine residues
This causes conformational changes that release Nrf2
Freed Nrf2 translocates to the nucleus
Nrf2 binds to ARE sequences, activating transcriptionIn vitro studies showed that compounds 5c, 5g, and 5h:
- Upregulated HO-1 expression in HT22 neuronal cells
- Increased GCLM levels, enhancing glutathione synthesis
- Reduced ROS accumulation in H₂O₂-challenged cells
- Protected against Aβ-induced toxicity in neuronal cultures
Neuroprotective Effects
In Vitro Results
In HT22 hippocampal neurons, the lead compounds demonstrated[@lao2026]:
In Vivo Efficacy
In Aβ transgenic C. elegans models, lead compounds demonstrated:
- Reduced paralysis: Improved locomotive function in Aβ-expressing worms
- Cognitive improvement: Enhanced learning and memory in behavioral assays
- Reduced oxidative stress: Decreased ROS markers in nervous tissue
- Good CNS drugability: Favorable pharmacokinetic properties for brain penetration
Molecular Docking
Computational studies confirmed that compound 5c:
- Binds to BuChE active site with favorable interactions (hydrogen bonds, hydrophobic contacts)
- Interacts with Keap1 at key cysteine residues (C151, C273, C288) that trigger Nrf2 release
Therapeutic Potential
Advantages of Dual-Targeting Approach
The ferulic acid carbamate derivatives offer several unique advantages:
Multi-target therapy: Addresses both cholinergic deficit and oxidative stress simultaneously
Disease-modifying potential: Nrf2 activation may slow disease progression through neuroprotection
Symptomatic relief: BuChE inhibition provides symptomatic benefit in cholinergic transmission
Reduced side effects: Selective BuChE sparing avoids peripheral cholinergic toxicity
Natural product origin: Ferulic acid provides a favorable safety profile based on historical useComparison with Existing AD Therapies
Clinical Translation Potential
Given the strong preclinical data:
- Phase I trials could assess safety, tolerability, and pharmacokinetics in healthy volunteers
- Phase II trials could evaluate cognitive endpoints in mild-to-moderate AD patients
- Combination potential: Could be combined with existing AChE inhibitors for enhanced effect
Cross-Linking
- [Nrf2 Pathway](/mechanisms/nrf2-pathway) — Master regulator of antioxidant response
- [Nrf2 Activation in Parkinson's Disease](/mechanisms/nrf2-activators-parkinsons)
- [Oxidative Stress in AD](/mechanisms/oxidative-stress-comparison)
- [Nrf2-Keap1 Pathway](/mechanisms/nrf2-keap1-pathway)
- [NRF2 Activator Therapy](/therapeutics/nrf2-activator-therapy) — Broader Nrf2 activation approaches
- [Antioxidant Therapy](/therapeutics/antioxidant-therapy-neurodegeneration)
- [Alpha-Lipoic Acid](/therapeutics/alpha-lipoic-acid-neurodegeneration) — Another antioxidant therapeutic
- [Curcumin Neurodegeneration](/therapeutics/curcumin-neurodegeneration) — Natural product with similar properties
- [Sulforaphane Nrf2 Neuroprotection](/therapeutics/sulforaphane-nrf2-neuroprotection)
- [BCHE Gene](/proteins/bche-protein) — Butyrylcholinesterase gene
- [NRF2 Protein](/proteins/nrf2)
- [KEAP1 Protein](/proteins/keap1)
- [HO-1 Protein](/proteins/ho-1)
- [GCLM Protein](/proteins/gclm-protein)
Related Disease Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
References
[Lao et al., Discovery of ferulic acid carbamate derivatives as dual-targeting agents of BuChE and Nrf2 for Alzheimer's disease (2026)](https://pubmed.ncbi.nlm.nih.gov/41873153/)
[Liu et al., Ferulic acid: a comprehensive review of its pharmacology in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Kumar et al., Butyrylcholinesterase: structure, function, and therapeutic targeting in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Sandberg & Nordberg, The Nrf2-ARE pathway as a therapeutic target in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
- [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
- [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
- [Prefrontal sensory gating circuit restoration via PV interneuron enhancement](/hypothesis/h-62f9fc90) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: PVALB
- [Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2
- [GFAP-Positive Reactive Astrocyte Subtype Delineation](/hypothesis/h-seaad-56fa6428) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: GFAP
- [Excitatory Neuron Vulnerability via SLC17A7 Downregulation](/hypothesis/h-seaad-7f15df4c) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: SLC17A7
- [SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction](/hypothesis/h-seaad-v4-5a7a4079) — <span style="color:#81c784;font-weight:600">0.62</span> · Target: SIRT3
Related Analyses:
- [Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄
- [Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) 🔄
- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
- [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
- [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Ferulic Acid Carbamate Derivatives for Alzheimer's Disease discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)